Company Overview and News

9
5 Fastest-Growing Stocks to Buy and Hold

2018-09-10 investorplace - 1
There’s no doubt about it. The bull market over the past decade has been defined by growth. Where there’s been growth, the fastest-growing stocks have seen share price over-performance.
SQ SHOP IRBT NFLX CHGG AAXN

139
9 High-Risk Stocks to Buy for Massive Rewards

2018-08-31 investorplace - 4
Slow and steady wins the race, as the old adage goes. But slow and steady can be a bit boring. Investors looking for stocks to buy, as a rule, should focus on high-quality, and preferably, lower-risk issues.
SGMS CHKVP CHGG CHKDH CHKVZ CHKDG MYL CHKDJ CHKDP SDRL CSCO FSLR CSIQ SUP GWP IBM SPLK CKRGZ EVRI SFL CHKWZ GWPH CHK CHK.WI TSLA

39
Barnes & Noble Education: After Integrating Acquisitions, Path To 60%+ Upside Becomes Clearer

2018-08-27 seekingalpha
BNED is fundamentally misunderstood and could double in the coming year as investors digest recent acquisitions and better understand the Company’s market position.
BNED AMZN PSO BKS CNGO CHGG

48
CHGG Stock Is an Undiscovered Long-Term Winner

2018-08-01 investorplace - 2
Digital education company Chegg (NYSE:CHGG) has been one of the hottest investments in the stock market for the past several years for a good reason. CHGG stock is up 400% over the past two years. During that stretch, the student-first education company has pivoted from renting out textbooks and study materials to running a connected learning platform with high-margin software revenues.
FB AMZN TWTR NFLX CHGG

2
Chegg, Inc (CHGG) CEO Dan Rosensweig on Q2 2018 Results - Earnings Call Transcript

2018-07-31 seekingalpha
Greetings, and welcome to the Chegg Second Quarter 2018 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation [Operator Instructions]. As a reminder, this conference is being recorded.
CHGG

4
Chegg (CHGG) Beats Q2 Earnings and Revenue Estimates

2018-07-30 zacks
Chegg (CHGG - Free Report) just came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.06 per share a year ago. These figures are adjusted for non-recurring items.
ALGN CHGG

2
CHGG / Chegg, Inc. 10-Q (Quarterly Report)

2018-07-30 sec.gov
Document Table of Contents
CHGG

2
Chegg, Inc. 2018 Q2 - Results - Earnings Call Slides

2018-07-30 seekingalpha
The following slide deck was published by Chegg, Inc. in conjunction with their 2018 Q2 earnings call.
CHGG

2
CHGG / Chegg, Inc. 8-K (Current Report)

2018-07-30 sec.gov
Document
CHGG

16
Internet Stocks' Q2 Earnings on Jul 30: CHGG, INST & More

2018-07-27 zacks
The second-quarter 2018 reporting cycle is in full swing and has been displaying encouraging trends, especially on the revenue side. Per the latest Earnings Outlook, total earnings of the 217 S&P 500 members, constituting 54.1% of the index, which have already reported are up 21.8% on a year-over-year basis (81.6% of the companies beat EPS estimates). Total revenues are up 8.8% (72.8% of the companies beat top-line estimates).
APPF FB EA SOHU GOOGL INST MSFT NVR CHGG TRN

4
Chegg (CHGG) Acquires StudyBlue, Bolsters Content Offering

2018-07-03 zacks - 2
Chegg, Inc. (CHGG - Free Report) acquired StudyBlue, Inc. — an online studying platform for high school and college students — for approximately $20.8 million in an all-cash transaction. Chegg’s shares closed Monday at $28.41, up 2.2% from Friday’s closing price. Chegg’s second-quarter and full-year guidance will not have any material impact due to the acquisition. However, the company expects a restructuring charge of approximately $1 million in 2019, for facility consolidation.
BL ABX EGAN BNFT CHGG ABX

9
CHGG / Chegg, Inc. 8-K (Current Report)

2018-07-02 sec.gov - 3
Document
CHGG

55
Under Armour Is A Winner - Cramer's Lightning Round (6/20/18)

2018-06-21 seekingalpha
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Wednesday, June 20.
PFPT NVCR CGNX UAA PANW WTW CHGG CYBR UA FEYE EMR BMY ROK

321
A Short Case For A Longer Term!

2018-06-20 seekingalpha - 10
Most investors should favor a longer-term time frame as the markets again record new highs after recovering from the first quarter pullback.
CRC ADAP ECYT LOXO NBIX ARWR SRPT TRXC CHGG SUPN RGNX ARNA TWLO IMMU NDAQ MRTX HEAR TTD

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 163092109